Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13926069 | 0.91 | RAB9A (0.43) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL13651456 | 0.88 | RAB9A (0.41) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL13651441 | 0.88 | RAB9A (0.41) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL10071672 | 0.87 | RAB9A (0.54) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL13531618 | 0.87 | RAB9A (0.41) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL4617880 | 0.87 | RAB9A (0.54) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL4337454 | 0.87 | RAB9A (0.54) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL13614205 | 0.87 | RAB9A (0.54) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL13914986 | 0.87 | RAB9A (0.41) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 | |
| SCHEMBL12640046 | 0.87 | RAB9A (0.41) | RAB9ANPC1KDM4ESMN1; SMN2GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642370-B2 | Method for preparing prostaglandin derivative | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20080033176-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033176-A1 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE | PTGIS, PTGS1, PTGER1 | RAB9A 1462/4885NPC1 2674/4885KDM4E 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.